Duopharma Biotech Bhd (XKLS:7148) Other Current Receivables: RM0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKLS:7148 Duopharma Biotech Bhd XKLS:7148
82 GF Score
Price RM1.22
GF Value RM1.53
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Duopharma Biotech Bhd Other Current Receivables?

Duopharma Biotech Bhd XKLS:7148 +0.83% 82 Other Current Receivables is RM0.0 Mil as of Mar. 2026. GuruFocus rates XKLS:7148 with a GF Score™ of 82/100 and a GF Value™ of RM1.53 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Duopharma Biotech Bhd's Other Current Receivables for the quarter that ended in Mar. 2026 was RM0.0 Mil.

Duopharma Biotech Bhd's annual Other Current Receivables declined from Dec. 2023 (RM10.06 Mil) to Dec. 2024 (RM5.49 Mil) and declined from Dec. 2024 (RM5.49 Mil) to Dec. 2025 (RM5.06 Mil).

Duopharma Biotech Bhd Other Current Receivables Related Terms

Duopharma Biotech Bhd Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Duopharma Biotech Bhd's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duopharma Biotech Bhd Other Current Receivables Chart

Duopharma Biotech Bhd Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.38 7.63 10.06 5.49 5.06

Duopharma Biotech Bhd Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 5.06 0.00
XKLS:7148
82GF Score
Duopharma Biotech Bhd XKLS:7148
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duopharma Biotech Bhd Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of RM0.0 Mil mean?
Duopharma Biotech Bhd (XKLS:7148) has a Other Current Receivables of RM0.0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Duopharma Biotech Bhd and its competitors.
Is Duopharma Biotech Bhd's Other Current Receivables too high?
Duopharma Biotech Bhd's current Other Current Receivables is RM0.0 Mil. Overall, Duopharma Biotech Bhd has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Other Current Receivables compare to ZTS and UTHR?
Duopharma Biotech Bhd's Other Current Receivables of RM0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Drug Manufacturers company?
A good Other Current Receivables depends on the Drug Manufacturers industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Duopharma Biotech Bhd and its competitors. Duopharma Biotech Bhd's current Other Current Receivables is RM0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.53, compared to a current price of RM1.22 — trading 20.3% below its estimated fair value. The current Other Current Receivables is RM0.0 Mil. Duopharma Biotech Bhd's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Other Current Receivables is RM0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?

Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued. The current stock price of RM1.22 is trading 20.3% below its estimated GF Value™ of RM1.53. GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.

Key valuation signals for XKLS:7148:

  • Other Current Receivables: RM0.0 Mil
  • GF Value™: RM1.53 vs. price of RM1.22 (20.3% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Duopharma Biotech Bhd Business Description

Address Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, SGR, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
82GF Score

Get the complete analysis for XKLS:7148

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

RM1.22
Price
RM1.53
GF Value